Lakefront Biotherapeutics NV (LKFT) — Cash Flow Quality Index
Lakefront Biotherapeutics NV (LKFT) has a Cash Flow Quality Index of -5.71x as of March 2026. Operating cash flow of $-82.75 Million is below net income of $14.49 Million, suggesting accrual-heavy earnings not yet converted to cash. For the full cash flow conversion analysis, see LKFT cash generation efficiency.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Lakefront Biotherapeutics NV Cash Flow Quality Index (2023–2025)
Historical Cash Flow Quality Index for Lakefront Biotherapeutics NV across 3 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore Lakefront Biotherapeutics NV debt service capacity to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Quality Index for Lakefront Biotherapeutics NV (2023–2025)
Year-by-year earnings quality comparison for Lakefront Biotherapeutics NV. See Lakefront Biotherapeutics NV working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | -0.80x | $-257.46 Million | $320.88 Million | ▲ +81.4% |
| 2024 | -4.32x | $-320.03 Million | $74.08 Million | ▼ -125.3% |
| 2023 | -1.92x | $-405.97 Million | $211.70 Million | — |